Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016

Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016
Published Aug 17, 2016
38 pages — Published Aug 17, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016, provides an overview of the Proliferative Vitreoretinopathy (PVR) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR)
- The report reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Proliferative Vitreoretinopathy (PVR) therapeutics and enlists all their major and minor projects
- The report assesses Proliferative Vitreoretinopathy (PVR) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Proliferative Vitreoretinopathy (PVR)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identi

  
Source:
Document ID
GMDHC8363IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Proliferative Vitreoretinopathy (PVR) Overview61
Therapeutics Development72
  Pipeline Products for Proliferative Vitreoretinopathy (PVR) Overview71
  Pipeline Products for Proliferative Vitreoretinopathy (PVR) Comparative Analysis81
Proliferative Vitreoretinopathy (PVR) Therapeutics under Development by Companies91
Proliferative Vitreoretinopathy (PVR) Therapeutics under Investigation by Universities/Institutes101
Proliferative Vitreoretinopathy (PVR) Pipeline Products Glance111
  Early Stage Products111
Proliferative Vitreoretinopathy (PVR) Products under Development by Companies121
Proliferative Vitreoretinopathy (PVR) Products under Investigation by Universities/Institutes131
Proliferative Vitreoretinopathy (PVR) Companies Involved in Therapeutics Development143
  Novartis AG141
  Promedior, Inc.151
  RXi Pharmaceuticals Corporation161
Proliferative Vitreoretinopathy (PVR) Therapeutics Assessment178
  Assessment by Monotherapy Products171
  Assessment by Target182
  Assessment by Mechanism of Action202
  Assessment by Route of Administration221
  Assessment by Molecule Type232
Drug Profiles257
  Antisense RNAi Oligonucleotide to Inhibit CTGF for PVR Drug Profile251
  Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy Drug Profile261
  LD-224 Drug Profile271
  PRM-167 Drug Profile282
  Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy Drug Profile301
  XOMA-089 Drug Profile311
Proliferative Vitreoretinopathy (PVR) Dormant Projects321
Proliferative Vitreoretinopathy (PVR) Product Development Milestones334
  Featured News &Press Releases331
    Apr 27, 2015: RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences331
    May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform341
    May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting351
    May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting361
Appendix372
  Methodology371
  Coverage371
  Secondary Research371
  Primary Research371
  Expert Panel Validation371
  Contact Us371
  Disclaimer381

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016" Aug 17, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Proliferative-Vitreoretinopathy-PVR-Pipeline-Review-H2-2016-2088-16390>
  
APA:
Global Markets Direct - Market Research. (2016). Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016 Aug 17, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Proliferative-Vitreoretinopathy-PVR-Pipeline-Review-H2-2016-2088-16390>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.